

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5411849

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JUAN R. DEL VALLE	01/12/2019
LINDSEY SHAW	03/07/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	UNIVERSITY OF SOUTH FLORIDA
<b>Street Address:</b>	3802 SPECTRUM BLVD.
<b>Internal Address:</b>	SUITE 100
<b>City:</b>	TAMPA
<b>State/Country:</b>	FLORIDA
<b>Postal Code:</b>	33612
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16234880
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(414)277-0656
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	414-271-6560
<b>Email:</b>	mkeipdocket@michaelbest.com
<b>Correspondent Name:</b>	MICHAEL BEST & FRIEDRICH LLP (USF)
<b>Address Line 1:</b>	100 E WISCONSIN AVENUE
<b>Address Line 2:</b>	SUITE 3300
<b>Address Line 4:</b>	MILWAUKEE, WISCONSIN 53202
<b>ATTORNEY DOCKET NUMBER:</b>	210112-9094-US03
<b>NAME OF SUBMITTER:</b>	WEI YAN
<b>SIGNATURE:</b>	/wei yan/
<b>DATE SIGNED:</b>	03/08/2019
<b>Total Attachments: 4</b>	
source=Signed_Assignment_210112-9094-US03#page1.tif	
source=Signed_Assignment_210112-9094-US03#page2.tif	
source=Signed_Assignment_210112-9094-US03#page3.tif	



A S S I G N M E N T

Pursuant to our obligation to **University of South Florida** (hereinafter referred to as "Assignee") having its principal place of business at:

3802 Spectrum Blvd.  
Suite 100  
Tampa, FL 33612

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we, **JUAN R. DEL VALLE** and **LINDSEY SHAW** confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest -

(1) in and to inventions described in a patent application titled "ANTIMICROBIAL ANALOGUES OF GRAMICIDIN S" for which we filed United States Patent Application No. 16/234,880 on December 28, 2018 (Atty. File No. 210112-9094-US03) (hereinafter "U.S. utility patent application"), which claims priority benefit to United States Provisional Patent Application No. 62/678,591, filed on May 30, 2018;

(2) in and to the U.S. utility patent application, and the U.S. provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, 35 U.S.C. §111(b) provisional, 35 U.S.C. §111(a), and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the U.S. utility patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on either or both of the U.S. utility patent application and the U.S. provisional patent application.


We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the

intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

Assignors hereby authorize the assignee or attorney of record to insert in the appropriate place in this document the application number and filing date of our application after execution of this Assignment.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

1/12/19  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Juan R. Del Valle

\_\_\_\_\_  
Date

\_\_\_\_\_  
Lindsey Shaw

A S S I G N M E N T

Pursuant to our obligation to **University of South Florida** (hereinafter referred to as "Assignee") having its principal place of business at:

3802 Spectrum Blvd.  
Suite 100  
Tampa, FL 33612

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we, **JUAN R. DEL VALLE** and **LINDSEY SHAW** confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest -

(1) in and to inventions described in a patent application titled "ANTIMICROBIAL ANALOGUES OF GRAMICIDIN S" for which we filed United States Patent Application No. 16/234,880 on December 28, 2018 (Atty. File No. 210112-9094-US03) (hereinafter "U.S. utility patent application"), which claims priority benefit to United States Provisional Patent Application No. 62/678,591, filed on May 30, 2018;

(2) in and to the U.S. utility patent application, and the U.S. provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, 35 U.S.C. §111(b) provisional, 35 U.S.C. §111(a), and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the U.S. utility patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on either or both of the U.S. utility patent application and the U.S. provisional patent application.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the

intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

Assignors hereby authorize the assignee or attorney of record to insert in the appropriate place in this document the application number and filing date of our application after execution of this Assignment.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

\_\_\_\_\_  
Date

03/07/19

\_\_\_\_\_  
Date

\_\_\_\_\_  
Juan R. Del Valle



\_\_\_\_\_  
Lindsey Shaw